<?xml version='1.0' encoding='utf-8'?>
<document id="10527640"><sentence text="P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil." /><sentence text="Digoxin, which has a very narrow therapeutic window, is one of the most commonly prescribed drugs in the treatment of congestive heart failure"><entity charOffset="0-7" id="DDI-PubMed.10527640.s2.e0" text="Digoxin" /></sentence><sentence text=" In some cases of atrial fibrillation digoxin is used in combination with verapamil"><entity charOffset="38-45" id="DDI-PubMed.10527640.s3.e0" text="digoxin" /><entity charOffset="74-83" id="DDI-PubMed.10527640.s3.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.10527640.s3.e0" e2="DDI-PubMed.10527640.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10527640.s3.e0" e2="DDI-PubMed.10527640.s3.e1" /></sentence><sentence text=" Verapamil can increase the plasma concentration of digoxin up to 60-90%"><entity charOffset="52-59" id="DDI-PubMed.10527640.s4.e0" text="digoxin" /></sentence><sentence text=" So far the precise mechanism of this pharmacokinetic drug-drug interaction is not known" /><sentence text=" Many studies suggest that verapamil reduces the renal clearance of digoxin"><entity charOffset="68-75" id="DDI-PubMed.10527640.s6.e0" text="digoxin" /></sentence><sentence text=" The energy-dependent membrane-bound transport enzyme, P-glycoprotein, may also be involved" /><sentence text=" Reports from oncology research show that verapamil can interact with P-glycoprotein as a modulator"><entity charOffset="42-51" id="DDI-PubMed.10527640.s8.e0" text="verapamil" /></sentence><sentence text=" Also taking into account that digoxin, like many anticancer drugs, is a substrate for P-glycoprotein, it is likely that P-glycoprotein modulation accounts for the digoxin-verapamil interaction"><entity charOffset="31-38" id="DDI-PubMed.10527640.s9.e0" text="digoxin" /><entity charOffset="164-171" id="DDI-PubMed.10527640.s9.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10527640.s9.e0" e2="DDI-PubMed.10527640.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10527640.s9.e0" e2="DDI-PubMed.10527640.s9.e1" /></sentence><sentence text=" Current knowledge suggest that the non-competitive digoxin-verapamil interaction is due to inhibition of P-glycoprotein activity by verapamil resulting in a decreased renal tubular elimination of digoxin"><entity charOffset="52-59" id="DDI-PubMed.10527640.s10.e0" text="digoxin" /><entity charOffset="197-204" id="DDI-PubMed.10527640.s10.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10527640.s10.e0" e2="DDI-PubMed.10527640.s10.e0" /><pair ddi="false" e1="DDI-PubMed.10527640.s10.e0" e2="DDI-PubMed.10527640.s10.e1" /></sentence><sentence text="" /></document>